Unknown

Dataset Information

0

Preventing Myocardial Injury Following Non-Cardiac Surgery: A Potential Role for Preoperative Antioxidant Therapy with Ubiquinone.


ABSTRACT: Over 240 million non-cardiac operations occur each year and are associated with a 15-20% incidence of adverse perioperative cardiovascular events. Unfortunately, preoperative therapies that have been useful for chronic ischemic heart diseases, such as coronary artery revascularization, antiplatelet agents, and beta-blockers have failed to improve outcomes. In a pre-clinical swine model of ischemic heart disease, we showed that daily administration of ubiquinone (coenzyme Q10, CoQ10) enhances the antioxidant status of mitochondria within chronically ischemic heart tissue, potentially via a PGC1?-dependent mechanism. In a randomized controlled trial, among high-risk patients undergoing elective vascular surgery, we showed that NT Pro-BNP levels are an important means of risk-stratification during the perioperative period and can be lowered with administration of CoQ10 (400 mg/day) for 3 days prior to surgery. The review provides background information for the role of oxidant stress and inflammation during high-risk operations and the potential novel application of ubiquinone as a preoperative antioxidant therapy that might reduce perioperative adverse cardiovascular outcomes.

SUBMITTER: Chen Q 

PROVIDER: S-EPMC7916807 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preventing Myocardial Injury Following Non-Cardiac Surgery: A Potential Role for Preoperative Antioxidant Therapy with Ubiquinone.

Chen Qun Q   Qi Steven S   Hocum-Stone Laura L   Lesnefsky Edward E   Kelly Rosemary F RF   McFalls Edward O EO  

Antioxidants (Basel, Switzerland) 20210210 2


Over 240 million non-cardiac operations occur each year and are associated with a 15-20% incidence of adverse perioperative cardiovascular events. Unfortunately, preoperative therapies that have been useful for chronic ischemic heart diseases, such as coronary artery revascularization, antiplatelet agents, and beta-blockers have failed to improve outcomes. In a pre-clinical swine model of ischemic heart disease, we showed that daily administration of ubiquinone (coenzyme Q<sub>10</sub>, CoQ<sub>  ...[more]

Similar Datasets

| S-EPMC7485855 | biostudies-literature
| S-EPMC6354048 | biostudies-literature
| S-EPMC7028328 | biostudies-literature
| S-EPMC8751857 | biostudies-literature
| S-EPMC5675103 | biostudies-literature
| S-EPMC3763989 | biostudies-literature
| S-EPMC3341084 | biostudies-literature
| S-EPMC4954612 | biostudies-literature
| S-EPMC6098731 | biostudies-literature
| S-EPMC4998548 | biostudies-literature